MX2022014892A - Metodos para preparar vesiculas extracelulares y usos de estas. - Google Patents

Metodos para preparar vesiculas extracelulares y usos de estas.

Info

Publication number
MX2022014892A
MX2022014892A MX2022014892A MX2022014892A MX2022014892A MX 2022014892 A MX2022014892 A MX 2022014892A MX 2022014892 A MX2022014892 A MX 2022014892A MX 2022014892 A MX2022014892 A MX 2022014892A MX 2022014892 A MX2022014892 A MX 2022014892A
Authority
MX
Mexico
Prior art keywords
methods
extracellular vesicles
preparing extracellular
evs
present disclosure
Prior art date
Application number
MX2022014892A
Other languages
English (en)
Inventor
Yonglian Sun
James Thomas Koerber
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2022014892A publication Critical patent/MX2022014892A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación se refiere a métodos y composiciones mejorados para preparar vesículas extracelulares (EV). La presente divulgación también se refiere a ensayos ELISA basados en EV novedosos y kits para llevar a cabo dichos ensayos, así como a métodos para producir anticuerpos contra antígenos particulares usando EV que comprenden antígeno unido a la membrana.
MX2022014892A 2020-06-01 2021-05-31 Metodos para preparar vesiculas extracelulares y usos de estas. MX2022014892A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063033014P 2020-06-01 2020-06-01
PCT/US2021/035072 WO2021247457A2 (en) 2020-06-01 2021-05-31 Methods for making extracellular vesicles and uses thereof

Publications (1)

Publication Number Publication Date
MX2022014892A true MX2022014892A (es) 2023-01-04

Family

ID=76943084

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014892A MX2022014892A (es) 2020-06-01 2021-05-31 Metodos para preparar vesiculas extracelulares y usos de estas.

Country Status (13)

Country Link
US (1) US20230090177A1 (es)
EP (1) EP4157866A2 (es)
JP (2) JP2023530600A (es)
KR (1) KR20230017822A (es)
CN (1) CN115667294A (es)
AR (1) AR122496A1 (es)
AU (1) AU2021285802A1 (es)
BR (1) BR112022024472A2 (es)
CA (1) CA3182473A1 (es)
IL (1) IL298599A (es)
MX (1) MX2022014892A (es)
TW (2) TWI814008B (es)
WO (1) WO2021247457A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3257258A1 (en) 2022-05-03 2023-11-09 Genentech, Inc. Anti-Ly6E antibodies, immunoconjugates, and their uses
CN115845083B (zh) * 2022-12-12 2025-04-11 南京逸微健华生物科技有限公司 一种靶向改造Expi293细胞外泌体递送siMMP13的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (es) 1967-05-23 1971-08-02 Pharmacia Ab
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5241053A (en) * 1990-09-05 1993-08-31 Takeda Chemical Industries, Ltd. Fused proteins comprising glycoprotein gD of HSV-1 and LTB
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7914792B2 (en) * 2003-02-14 2011-03-29 Exothera L.L.C. Methods and compounds for raising antibodies and for screening antibody repertoires
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US9737480B2 (en) * 2012-02-06 2017-08-22 President And Fellows Of Harvard College ARRDC1-mediated microvesicles (ARMMs) and uses thereof
JP6786074B2 (ja) * 2016-04-04 2020-11-18 国立研究開発法人医薬基盤・健康・栄養研究所 エキソソーム標的ｄｎａワクチン
JP2019017341A (ja) * 2017-07-20 2019-02-07 国立研究開発法人国立がん研究センター 標識小胞及びその製造方法

Also Published As

Publication number Publication date
KR20230017822A (ko) 2023-02-06
WO2021247457A2 (en) 2021-12-09
EP4157866A2 (en) 2023-04-05
TW202423962A (zh) 2024-06-16
AR122496A1 (es) 2022-09-14
TWI885439B (zh) 2025-06-01
IL298599A (en) 2023-01-01
US20230090177A1 (en) 2023-03-23
CN115667294A (zh) 2023-01-31
BR112022024472A2 (pt) 2022-12-27
WO2021247457A3 (en) 2022-01-13
TWI814008B (zh) 2023-09-01
TW202204414A (zh) 2022-02-01
JP2023530600A (ja) 2023-07-19
JP2026027260A (ja) 2026-02-18
AU2021285802A1 (en) 2022-12-08
CA3182473A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
CO2020001491A2 (es) Molécula de polipéptido con especificidad dual mejorada
BR112022024228A2 (pt) Construtos para receptores de antígeno quiméricos
MX2022014892A (es) Metodos para preparar vesiculas extracelulares y usos de estas.
MX2016012855A (es) Receptores de antigeno quimerico especifico de cd33 para inmunoterapia de cancer.
MX2021007320A (es) Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor.
CL2022003515A1 (es) Moléculas agonistas de unión al antígeno cd28 que se dirigen a her2
BR112016022819A2 (pt) uso de um método, método para a produção de um anticorpo com reatividade cruzada para humano e cinomolgo e anticorpo com reatividade cruzada para humano e cinomolgo
PE20150643A1 (es) Anticuerpos de reaccion cruzada anti-jagged 1/jagged 2 anticuerpos anti-jagged activables y metodos de uso de los mismos
MX2020005143A (es) Uso de celulas t modificadas por receptor de antigeno quimerico para tratar cancer.
CL2016001256A1 (es) Composiciones y métodos para anticuerpos dirigidos factor de p (divisional de sol. n° 1640-14).
CO2020014343A2 (es) Anticuerpos específicos para cd3 y sus usos
CR20150095A (es) Proteinas de unión a antígeno capaces de unirse a linfopoyetina estromática tímica
MX2020001752A (es) Anticuerpos anti-cd3 y metodos de uso.
GT201100023A (es) Anticuerpos neutralizantes del virus anti - influenza a y usos de los mismos
MX2017001211A (es) Receptores de antigenos quimericos ror1 (ntrkr1) especificos para inmunoterapia del cancer.
CO6251323A2 (es) Nuevos compuestos
CO6331370A2 (es) Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos
UA114502C2 (uk) Вакцина mycoplasma hyopneumoniae
MX2012000372A (es) Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas.
WO2019145475A3 (en) Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof
MX342235B (es) Metodo optimizado para captura de anticuerpo por cromatografia de modo mixto.
MX389765B (es) Anticuerpos humanizados que transmigran a traves de la barrera hematoencefalica y usos de los mismos.
DE602004020489D1 (de) Verfahren, kits und zusammensetzungen zur entwicklung und anwendung von für antigene niedriger immunogenizität spezifischen monoklonalen antikörpern
PH12020551948A1 (en) Monospecific and multispecific anti-tmeff2 antibodies and their uses
AR126556A1 (es) Anticuerpos de dominios fc heterodiméricos